????中國政府指控葛蘭素史克（GlaxoSmithKline）前任中國區(qū)負(fù)責(zé)人馬克銳為提高藥品銷量而行賄醫(yī)生和醫(yī)療機(jī)構(gòu)。

????中國公安部（the Ministry of Public Security）經(jīng)濟(jì)犯罪偵察局副局長高峰指出，馬克銳運(yùn)營著一張“巨大的行賄網(wǎng)”。

????新華社稱，在馬克銳的經(jīng)營下，這家公司中國區(qū)的營業(yè)額從2009年的39億元上升到了2012年的69億元。高峰說：“葛蘭素史克的行賄活動貫穿了它在中國的整個業(yè)務(wù)運(yùn)營。”

????據(jù)悉，為尋求行賄資金來源，葛蘭素史克大幅提升了藥物成本，它的藥品在中國的售價甚至達(dá)到了其他國家的7倍。

????葛蘭素史克在聲明中回應(yīng)相關(guān)指控時指出：“我們非常嚴(yán)肅地對待這些指控。它們十分令人擔(dān)憂，而且也與葛蘭素史克的價值觀背道而馳。我們將繼續(xù)就此事全面配合政府機(jī)構(gòu)。”

????這一舉措意味著中國計劃采取更為強(qiáng)硬的措施來打擊外國高管的腐敗行為。中國最近在國內(nèi)政府官員以及本土高管的腐敗問題上采取了強(qiáng)硬的立場，但腐敗仍然是一個大問題。

????新華社稱，除了于2013年7月離任的馬克銳之外，中國政府還指控這家公司的高管張國維和趙虹燕行賄北京和上海地區(qū)的官員。案件于去年6月開始調(diào)查，還涉及其他46名人員。

????高峰說，葛蘭素史克還曾試圖阻撓執(zhí)法機(jī)關(guān)的調(diào)查。目前尚不清楚馬克銳將面臨什么樣的懲罰，也不知道中國政府將在什么時候會正式他，或者說到底會不會起訴。（財富中文網(wǎng)）

????譯者：翔

????Chinese authorities have accused GlaxoSmithKline's former China chief, Mark Reilly, of ramping up drug sales by bribing doctors and healthcare organizations.

????Gao Feng, deputy director of China's Ministry of Public Security's economic crimes unit, said Reilly operated a "massive bribery network."

????Under Reilly, revenue in China rose from 3.9 billion yuan in 2009 to 6.9 billion in 2012, according to the news agency Xinhua. "GSK's bribery activities ran through its entire operations in China," Gao said.

????In order to fund the bribery, Glaxo (GSK) allegedly bumped up drug costs, charging as much as seven times more than in other countries.

????"We take the allegations that have been raised very seriously," Glaxo said in a statement in response to the accusation. "They are deeply concerning to us and contrary to the values of GlaxoSmithKline. We will continue to fully co-operate with the authorities in this matter."

????The action signals China's plans to take aggressive action against corruption by foreign executives. The country has recently taken a tougher stance on corruption by its own political leaders and local executives, but corruption remains a huge problem.

????Along with Reilly, who left Glaxo in July 2013, Chinese officials accused fellow executives Zhang Guowei and Zhao Hongyan, of bribing officials in Beijing and Shanhai, Xinhua said. An additional 46 others have been implicated in the case, which began last June.

????Gao said that Glaxo also had tried to disrupt the law enforcement investigation. It's unclear what kind of punishment Reilly faces or when he will be formally indicted, if at all.